文献速递头颈部肿瘤放疗

鼻咽癌管理近期进展的批判性综述:迈向精准实践

Precision in Practice: A Critical Overview of Recent Advances in Nasopharyngeal Cancer Management.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-07

该综述聚焦鼻咽癌(NPC)放疗技术进步、新型系统药物及疾病生物学认知提升带来的疗效改善,强调在维持疾病控制的同时减少治疗相关毒性。文章汇总近6年随机临床试验数据,覆盖低危降阶治疗、同步期耐受性、局部晚期强化、血浆EBV DNA个体化、靶区与危及器官优化及复发转移管理六大领域,反映向风险适配的个体化管理转变。

要点

  • 精准IMRT与新型系统药物推动NPC疗效提升,毒性最小化与功能保全日益重要。
  • 血浆EBV DNA用于治疗个体化是精准管理的关键方向之一。
  • 低危降阶、同步期耐受性优化与局部晚期强化构成风险适配治疗主线。

核心结论

  • NPC管理正转向更个体化、风险适配的模式,兼顾生存与生活质量。

研究设计与样本

  • 批判性综述,汇总随机临床试验数据,重点纳入近6年发表的研究。

主要发现

  • 精准图像引导IMRT、新型系统药物及对疾病生物学的理解共同改善了NPC患者结局。
  • NPC好发于较年轻的中年患者,治愈后预期寿命长,使毒性最小化与功能保全愈发重要。
  • 近5年多项临床试验与大型当代系列研究为平衡肿瘤疗效与功能保全提供了优化策略。

关键数值与推荐

  • 综述覆盖5大关键领域:低危疾病降阶治疗、同步期耐受性改善策略、局部晚期强化治疗、血浆EBV DNA个体化应用、靶区勾画与危及器官保护及复发转移管理。

临床怎么用

  • 临床应依据风险分层选择降阶或强化策略,并利用血浆EBV DNA辅助治疗个体化决策。
  • 在追求肿瘤控制的同时,需重视靶区优化与危及器官保护以降低治疗相关毒性。

局限性

  • 为批判性综述而非原始研究,未报告统一样本量、效应量或P值等定量合并结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for patients with nasopharyngeal carcinoma (NPC) have improved significantly due to advances in radiation therapy technology, such as precision image guided intensity modulated radiation therapy, the emergence of novel systemic agents, and a growing understanding of disease biology and clinical behavior. Minimizing treatment-related toxicities while maintaining effective disease control is increasingly important in NPC, especially given its predilection for younger middle-aged patients with a long life expectancy after the cure of their disease. Over the past 5 years, multiple clinical trials and large contemporary series have offered valuable insights into optimizing treatment strategies that balance oncologic efficacy with functional preservation, positioning NPC as one of the most rapidly evolving head and neck cancer sites in the pursuit of precision oncology. This critical review summarizes data from randomized clinical trials, with a particular emphasis on studies published in the past 6 years, across 5 key areas: (1) treatment deintensification for low-risk disease; (2) strategies to improve treatment tolerability during the concurrent phase; (3) intensified treatment approaches for locoregionally advanced NPC; (4) utility of plasma Epstein-Barr virus DNA for treatment personalization; (5) tailored radiation therapy target volume delineation and organ-at-risk sparing; and (6) management strategies for recurrent and metastatic NPC. Together, these developments reflect a paradigm shift toward increasingly personalized, risk-adapted management of NPC that prioritizes both survival and quality of life.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Huang SH, Ng WT, Bakst RL, et al. Precision in Practice: A Critical Overview of Recent Advances in Nasopharyngeal Cancer Management. Int J Radiat Oncol Biol Phys. 2025. PMID: 41365475. doi:10.1016/j.ijrobp.2025.11.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。